Zacks Investment Research
23 Jun 2026, 22:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Adma Biologics (ADMA) currently holds a Zacks Rank of #5, which is categorized as a 'Strong Sell'. — A Strong Sell rating from a quantitative model typically signals a bearish outlook and potential price decline.
-0.60The Zacks Consensus EPS estimate for Adma Biologics has decreased by 2.38% over the last 30 days. — Downward revisions in earnings estimates generally reduce investor confidence and put downward pressure on the stock price.
-0.40Adma Biologics is trading at a Forward P/E ratio of 10.45, which is a significant discount compared to its industry average of 21.4. — A lower valuation relative to peers can be seen as an attractive entry point for value investors.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Analysts expect Adma Biologics to report earnings of $0.16 per share and revenue of $125.77 million in its upcoming quarterly release. — These projections represent modest year-over-year growth, providing a baseline for market reaction upon actual release.
Which stocks this story touches
Despite a small daily price gain, the company holds a Zacks Rank of #5 (Strong Sell) and has seen a decrease in consensus EPS estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
